There is 1 paper on brain-derived phosphorylated TAU217 in aging research: 1 observational study in people.
1 paper studies it2 findings
1 new paper in 30 daysSee all 1 papers on brain-derived phosphorylated TAU217
“BD‐pTau217 and total pTau217 had similar discrimination (full‐follow‐up AUC = 0.66 each; high‐versus‐low hazard ratios [HRs]; 95% confidence interval [CIs]: 2.8 [1.89–4.06] and 2.9 [1.96–4.35], respectively).”
- Humans1
Associations
2Progression to amyloid PET positivity
upin humans1HR 10.54
1 study
Progression to amyloid PET positivity
upin humans1HR 10.54
Brain-derived phosphorylated TAU217 predicts progression to amyloid PET positivity in humans (Initially amyloid-negative participants) (2.5 years: HR 10.54 (95% CI 2.3–48.1), tdAUC 0.82 versus 0.69; 4 years: HR 7.03 (95% CI 1.9–25.6), tdAUC 0.77 versus 0.64).
HumansInitially amyloid-negative participantsplasma2.5 and 4 years
Progression to mild cognitive impairment or Alzheimer's disease dementia
upin humans1HR 2.8
1 study
Progression to mild cognitive impairment or Alzheimer's disease dementia
upin humans1HR 2.8
Brain-derived phosphorylated TAU217 predicts progression to mild cognitive impairment or Alzheimer's disease dementia in humans (Cognitively unimpaired participants; high versus low baseline biomarker) (HR 2.8, 95% CI 1.89–4.06; AUC 0.66).
HumansCognitively unimpaired participants; high versus low baseline biomarkerplasmaMedian follow-up of 6 yearsn = 508
More on Progression to mild cognitive impairment or Alzheimer's disease dementia